[go: up one dir, main page]

WO2006016275A3 - Arn interférant spécifique vis-à-vis de la gastrine - Google Patents

Arn interférant spécifique vis-à-vis de la gastrine

Info

Publication number
WO2006016275A3
WO2006016275A3 PCT/IB2005/002686 IB2005002686W WO2006016275A3 WO 2006016275 A3 WO2006016275 A3 WO 2006016275A3 IB 2005002686 W IB2005002686 W IB 2005002686W WO 2006016275 A3 WO2006016275 A3 WO 2006016275A3
Authority
WO
WIPO (PCT)
Prior art keywords
gastrin
molecules
rnai
specific interfering
rnai molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/002686
Other languages
English (en)
Other versions
WO2006016275A2 (fr
Inventor
Susan A Watson
Anna Grabowska
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aphton Corp
Original Assignee
Aphton Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aphton Corp filed Critical Aphton Corp
Priority to CA002576576A priority Critical patent/CA2576576A1/fr
Priority to AU2005270917A priority patent/AU2005270917A1/en
Priority to EP05775595A priority patent/EP1778841A2/fr
Publication of WO2006016275A2 publication Critical patent/WO2006016275A2/fr
Publication of WO2006016275A3 publication Critical patent/WO2006016275A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/595—Gastrins; Cholecystokinins [CCK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des molécules d'acide ribonucléique interférant spécifique vis-à-vis de la gastrine (ARNi) qui exercent une régulation négative sur le gène de l'hormone gastrine. Les molécules d'ARNi de l'invention sont des molécules d'ARN double brin qui peuvent comprendre des bases modifiées et des liaisons qui ne sont pas des liaisons de type phosphate entre les bases. Les brins complémentaires des molécules d'ARNi de l'invention peuvent être liés par une chaîne de nucléotides ou par des groupes de liaison qui ne sont pas des nucléotides. Les molécules d'ARNi de l'invention peuvent être incorporées dans une formulation pharmaceutique utile dans un procédé servant à traiter des maladies ou affections médiées par la gastrine dont des tumeurs médiées par la gastrine, la maladie du reflux gastro-oesophagien (GERD), le syndrome de Zollinger-Ellison, l'hypergastrinémie, l'anémie pernicieuse, l'ulcère gastrique, l'ulcère duodénal et l'infection par H. pylori.
PCT/IB2005/002686 2004-08-11 2005-08-10 Arn interférant spécifique vis-à-vis de la gastrine Ceased WO2006016275A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002576576A CA2576576A1 (fr) 2004-08-11 2005-08-10 Arn interferant specifique vis-a-vis de la gastrine
AU2005270917A AU2005270917A1 (en) 2004-08-11 2005-08-10 Gastrin-specific interfering RNA
EP05775595A EP1778841A2 (fr) 2004-08-11 2005-08-10 Arn interférant spécifique vis-à-vis de la gastrine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60069604P 2004-08-11 2004-08-11
US60/600,696 2004-08-11

Publications (2)

Publication Number Publication Date
WO2006016275A2 WO2006016275A2 (fr) 2006-02-16
WO2006016275A3 true WO2006016275A3 (fr) 2006-05-18

Family

ID=35759261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002686 Ceased WO2006016275A2 (fr) 2004-08-11 2005-08-10 Arn interférant spécifique vis-à-vis de la gastrine

Country Status (5)

Country Link
EP (1) EP1778841A2 (fr)
KR (1) KR20070062515A (fr)
AU (1) AU2005270917A1 (fr)
CA (1) CA2576576A1 (fr)
WO (1) WO2006016275A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1608984A2 (fr) 2003-03-28 2005-12-28 Aphton Corporation Dosages immunologiques pour la detection de l'hormone gastrine
US8889640B1 (en) * 2008-06-20 2014-11-18 Jill P. Smith Composition and method for the treatment of gastrin mediated cancers
AU2018283284B2 (en) 2017-06-15 2024-05-16 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
EP4259195A4 (fr) * 2021-01-13 2024-12-11 Cancer Advances, Inc., Compositions et procédés destinés à la prévention de tumeurs et de cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010180A1 (fr) * 2001-07-23 2003-02-06 The Board Of Trustees Of The Leland Stanford Junior University Methodes et compositions pour l'inhibition induite par l'arni de l'expression genetique chez des mammiferes
WO2004042061A1 (fr) * 2002-11-08 2004-05-21 Klaus Strebhardt Composition pharmaceutique de suppression de l'expression non souhaitee d'un gene

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010180A1 (fr) * 2001-07-23 2003-02-06 The Board Of Trustees Of The Leland Stanford Junior University Methodes et compositions pour l'inhibition induite par l'arni de l'expression genetique chez des mammiferes
WO2004042061A1 (fr) * 2002-11-08 2004-05-21 Klaus Strebhardt Composition pharmaceutique de suppression de l'expression non souhaitee d'un gene

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GRABOWSKA A ET AL: "Downregulation of the gastrin gene using small interfering RNA", REGULATORY PEPTIDES, vol. 122, no. 1, September 2004 (2004-09-01), & 15TH INTERNATIONAL SYMPOSIUM ON REGULATORY PEPTIDES; TOULOUSE, FRANCE; SEPTEMBER 19 -22, 2004, pages 46, XP009061814, ISSN: 0167-0115 *
SINGH P ET AL: "TUMORIGENICITY OF A HUMAN COLON CANCER CELL LINE IS SIGNIFICANCE REDUCED IN VIVO, IN THE PRESENCE OF COLON CANCER CELLS OVEREXPRESSING ANTISENSE GASTRIN MRNA: ROLE OF INHIBITORY (ENDOCRINE) FACTORS IN THE OBSERVED BYSTANDER EFFECTS", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, US, vol. 114, no. 4, PART 2, 15 April 1998 (1998-04-15), pages A680, XP008056925, ISSN: 0016-5085 *
SMITH J P ET AL: "Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer", CANCER LETTERS, NEW YORK, NY, US, vol. 135, no. 1, 8 January 1999 (1999-01-08), pages 107 - 112, XP002357825, ISSN: 0304-3835 *
TAKHAR A S ET AL: "The role of gastrin in colorectal carcinogenesis.", THE SURGEON : JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND. OCT 2004, vol. 2, no. 5, October 2004 (2004-10-01), pages 251 - 257, XP009061845, ISSN: 1479-666X *
WATSON S ET AL: "GASTRIN INHIBITION INCREASES THE POTENCY OF CYTOTOXIC AGENTS IN PANCREATIC CANCER", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, US, vol. 122, no. 4, SUPPL 1, April 2002 (2002-04-01), pages A241, XP008056958, ISSN: 0016-5085 *

Also Published As

Publication number Publication date
AU2005270917A8 (en) 2006-02-16
AU2005270917A1 (en) 2006-02-16
EP1778841A2 (fr) 2007-05-02
CA2576576A1 (fr) 2006-02-16
KR20070062515A (ko) 2007-06-15
WO2006016275A2 (fr) 2006-02-16

Similar Documents

Publication Publication Date Title
WO2010141511A3 (fr) Polynucléotides pour interférence arn multivalente, compositions et procédés pour les utiliser
ATE557088T1 (de) Pankreasinsel-mikro-rna und verfahren zu ihrer unterdrückung
WO2007031877A3 (fr) Modulation de proprietes immunostimulantes de petits arn interferents (petits arni) par modification de nucleotides
SI2258847T1 (sl) Nadaljnje nove oblike molekul interferenčne RNA
WO2006119266A3 (fr) Micro-arn humains et procedes d'inhibition de ceux-ci
WO2007051045A3 (fr) Compositions et methodes destinees a inhiber l'expression du gene huntingtine
CA2513809A1 (fr) Derives lipophiles d'acide ribonucleique a double brin
WO2008036406A3 (fr) Compositions et procédés se rapportant à une thérapie par glissement de protéines pour la distrophie myotonique
WO2006026388A3 (fr) Techniques d'amplification d'acide nucleique avec une seule amorce
WO2009013620A3 (fr) Recombinaison homologue
EP1167461A3 (fr) Procédé de conditionnement de pigments organiques
WO2005089929A3 (fr) Surfaces modifiees en tant que supports solides pour la purification d'acides nucleiques
WO2006066203A3 (fr) Molecules de petit arn interferent (sirna) destinees a la modulation de la superoxyde dismutase (sod)
ATE528397T1 (de) Bei krebs überexprimiertes gen
WO2006016275A3 (fr) Arn interférant spécifique vis-à-vis de la gastrine
WO2002083943A3 (fr) Procede a microreseau permettant d'enrichir des fragments d'adn provenant de melanges complexes
WO2009027978A8 (fr) Séquences d'acides nucléiques comprenant un site de liaison nf-kb dans la région promotrice de la o(6)-méthylguanine-adn-méthyl transférase (mgmt) et leur utilisation pour le traitement du cancer et de troubles de l'immunité
Lou et al. Oligonucleotides containing a piperazino-modified 2′-amino-LNA monomer exhibit very high duplex stability and remarkable nuclease resistance
WO2002061110A3 (fr) Derives d'acide nucleique
WO2005110067A3 (fr) Procede et compositions destines a l'interference d'arn
WO2009105691A3 (fr) Utilisations de pentamidine et de composés associés
EP1479783A3 (fr) Méthode d'amplification PCR, set d'amorces pour la PCR, produit de PCR et methode de détection d'acides nucléiques utilisant la PCR.
WO2008108843A3 (fr) Procédés et kits pour amplifier l'adn
WO2006029076A3 (fr) Elements genetiques propres a des plantes et cassettes de transfert pour la transformation de plantes
WO2005090572A3 (fr) Compositions et procédés servant à traiter un cancer du pancréas

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2576576

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200580027254.1

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007525384

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005270917

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005775595

Country of ref document: EP

Ref document number: 1731/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020077005675

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2005270917

Country of ref document: AU

Date of ref document: 20050810

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005270917

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005775595

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005775595

Country of ref document: EP